There is a growing application of integrated and continuous bioprocessing (ICB) for
manufacturing recombinant protein therapeutics produced from mammalian cells. At first …

The biopharmaceutical market has experienced a tremendous growth in the last years.
However, this growth should be balanced considering the difficulty in bioproduct …

Single-column (batch) preparative chromatography is the technique of choice for purification
of biotherapeutics but it is often characterized by an intrinsic limitation in terms of yield-purity …

Biopharmaceutical manufacture is transitioning from batch to integrated and continuous
biomanufacturing (ICB). The common framework for most ICB, potentially enables a global …

Implementation of continuous in lieu of batch upstream processing (USP) and downstream
process (DSP) for the production of recombinant therapeutic protein is a significant …

An 8 ton per year manufacturing facility is described based on the framework for integrated
and continuous bioprocessing (ICB) common to all known biopharmaceutical …

The COVID-19 pandemic highlighted the urgent need for life-saving treatments, including
vaccines, drugs, and therapeutic antibodies, delivered at unprecedented speed. During this …

Hollow fiber‐based membrane filtration has emerged as the dominant technology for cell
retention in perfusion processes yet significant challenges in alleviating filter fouling remain …

Stable operation in mammalian perfusion cell cultures can be achieved using a waste
(bleed) stream to remove excess biomass from the reactor. This stream is often considered …

Therapeutic oligonucleotides (ONs) are typically manufactured via solid-phase synthesis,
characterized by limited scalability and huge environmental footprint, limiting their …